ZCM
YMAB

Ziegler Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Ziegler Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$577K Buy
+35,461
New +$478K 0.02% 342

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ziegler Capital Management's YMAB Position: Q1 2024 in Review

Ziegler Capital Management opened a new position in Y-mAbs Therapeutics (YMAB) in Q1 2024: 35,461 shares worth $577K. The stake represents 0.02% of the portfolio and ranks #342 among its holdings.

96 funds tracked by Wall St. Rank hold YMAB as of Q1 2024.

  • Ziegler Capital Management held 35,461 shares of Y-mAbs Therapeutics worth $577K as of Q1 2024.
  • Y-mAbs Therapeutics was a new Ziegler Capital Management position in Q1 2024.
  • Y-mAbs Therapeutics made up 0.02% of Ziegler Capital Management's portfolio in Q1 2024, its #342 holding.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2024.

Based on Ziegler Capital Management's 13F filing for Q1 2024, filed 15 May 2024.